Clinical trials: Alzheimer Disease 2
Alzheimer Disease
An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum
The purpose of this study is to evaluate the long-term safety and tolerability of JNJ-54861911 in participants in the early Alzheimer's disease (AD [progressive brain disease that slowly destroys memory and thinking skills, and…
- Trial name
- NCT02406027
- Testing
- JNJ-54861911, 10 mg, JNJ-54861911, 25 mg, JNJ-54861911, 5 mg
- Where
- 17 sites in Belgium, France and 4 more
- Volunteers
- 90 people
- Sponsor
- Janssen Research & Development, LLC
TTR-mediated Amyloidosis
A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis
The purpose of this study was to evaluate the safety and clinical activity of long-term dosing with revusiran (ALN-TTRSC). Dosing has been discontinued; patients are being followed-up for safety.
- Trial name
- NCT02292186
- Testing
- Revusiran (ALN-TTRSC)
- Where
- 5 sites in United States, Canada and 1 more
- Volunteers
- 25 people
- Sponsor
- Alnylam Pharmaceuticals
Amnestic Mild Cognitive Impairment, Alzheimer's Disease
An Open-Label Study Investigating MK-8931 in Participants With Mild and Moderate Hepatic Insufficiency (MK-8931-016)
This study consists of Part I and an optional Part II. The purpose of Part I is to compare the plasma pharmacokinetics of verubecestat (MK-8931) following administration of a single oral dose of 40 mg MK-8931 to participants with…
- Conditions
- Amnestic Mild Cognitive Impairment, Alzheimer's Disease, Prodromal Alzheimer's Disease
- Trial name
- NCT02910739
- Testing
- MK-8931
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer's Disease
A Multiple Dose Study of PF-04360365 In Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to determine whether multiple dose administration is safe and well tolerated in patients with mild to moderate Alzheimer's Disease.
- Trial name
- NCT00945672
- Testing
- PF-04360365 10 mg/kg, PF-04360365 7.5 mg/kg
- Where
- 4 sites in Sweden
- Volunteers
- 36 people
- Sponsor
- Pfizer
Alzheimers Disease
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
The purpose of this study was to test whether two investigational drugs called CAD106 and CNP520, administered separately, could slow down the onset and progression of clinical symptoms associated with Alzheimer's disease (AD) in…
- Trial name
- GS1 (NCT02565511)
- Testing
- CAD106 Immunotherapy, CNP520, Alum
- Where
- 129 sites in United States, Australia and 8 more
- Volunteers
- 480 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
Exercise and the Receptor for Advanced Glycation End Products (RAGE)
This study examines the effects of 12-weeks of aerobic exercise training on the mechanisms driving RAGE-mediated inflammation in type 2 diabetic humans.
- Trial name
- NCT03534687
- Testing
- Aerobic Exercise
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Michigan
Alzheimer Disease
A Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease
This is a randomized, double-blind, placebo-controlled, parallel-group comparison study in subjects with Alzheimer's Disease. Following first screening period, subjects will be randomly assigned into one of the following arms…
- Trial name
- NCT03117738
- Testing
- AstroStem
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Nature Cell Co. Ltd.
Alzheimer Disease
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
This is a randomized double-blind Placebo-controlled, Phase 2 study comparing bryostatin to placebo for the treatment of moderately severe to severe Alzheimer's disease in subjects not receiving memantine treatment.
- Trial name
- NCT03560245
- Testing
- Bryostatin
- Where
- 28 sites in United States
- Volunteers
- 108 people
- Sponsor
- Neurotrope Bioscience, Inc.
Alzheimer's Disease
Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease
A medicine that is FDA-approved for bone marrow stimulation (called Leukine) will be tested for its ability to be tolerated by Alzheimer's disease patients and potentially to improve their memory.
- Trial name
- NCT01409915
- Testing
- Sagramostim
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of Colorado, Denver
Alzheimer Disease
S-Equol in Alzheimer's Disease 2 Trial
By doing this study researchers hope to learn if S-equol, a compound that acts like estrogen in the body, causes an increase in mitochondrial activity.
- Trial name
- SEAD2 (NCT03101085)
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Russell Swerdlow
Alzheimer's Disease, Dementia With Lewy Bodies
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
This study seeks to evaluate the effect of intepirdine (RVT-101) on gait and balance in patients with Alzheimer's Disease, Dementia with Lewy Bodies or Parkinson's Disease Dementia.
- Conditions
- Alzheimer's Disease, Dementia With Lewy Bodies, Parkinson's Disease Dementia
- Trial name
- NCT02910102
- Testing
- RVT-101 35 mg
- Where
- 11 sites in United States
- Volunteers
- 38 people
- Sponsor
- Axovant Sciences Ltd.
Cognitive Dysfunction, Alzheimer's Disease
A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities
The primary objective of the study is to assess the safety impact of continuing aducanumab dosing in asymptomatic Amyloid-related Imaging Abnormalities (ARIA) in participants with mild cognitive impairment (MCI) due to…
- Trial name
- EVOLVE (NCT03639987)
- Testing
- Aducanumab
- Where
- 22 sites in United States
- Volunteers
- 52 people
- Sponsor
- Biogen
Alzheimer's Disease
A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to compare the effectiveness and safety of 2 years of treatment with galantamine as compared with placebo of patients who have mild to moderately severe Alzheimer's disease (AD).
- Trial name
- NCT00679627
- Testing
- Galantamine
- Where
- 95 sites in Czechia, Estonia and 10 more
- Volunteers
- 2,051 people
- Sponsor
- Janssen Research & Development, LLC
Agitation Associated With, Alzheimer's Disease
A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation
To compare the efficacy of 2 fixed doses of brexpiprazole with placebo in participants with agitation associated with dementia of the Alzheimer's type.
- Conditions
- Agitation Associated With, Alzheimer's Disease, Alzheimer's Type, Mental Disorder
- Trial name
- NCT01862640
- Testing
- Brexpiprazole, OPC-34712
- Where
- 85 sites in United States, Croatia and 5 more
- Volunteers
- 433 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Agitation Associated With Alzheimer's Dementia, Alzheimer Dementia
A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type
This study compares the efficacy of 2 doses of brexpiprazole with placebo in participants with agitation associated with dementia of the Alzheimer's type.
- Trial name
- NCT03548584
- Testing
- Brexpiprazole
- Where
- United States
- Volunteers
- 345 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Alzheimer's Disease
Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202)
The primary objective is to evaluate the efficacy of T-817MA as measured by ADAS-cog and ADCS-CGIC. The secondary objectives are: To evaluate the safety and tolerability of T-817MA measured by clinical safety laboratories…
- Trial name
- NCT02079909
- Testing
- T-817MA-H, T-817MA-L
- Where
- 50 sites in United States
- Volunteers
- 482 people
- Sponsor
- FUJIFILM Toyama Chemical Co., Ltd.
Primary Progressive Aphasia
Communication Bridge 2
This study will use a randomized controlled trial design to evaluate the effect of two evidence-based treatments for adults with mild Primary Progressive Aphasia (PPA).
- Trial name
- CB2 (NCT03371706)
- Testing
- Communication Bridge™, Evidence-Based Impairment Focused
- Where
- United States
- Volunteers
- 190 people
- Sponsor
- University of Chicago
Alzheimer Disease
Tau Screening Study in Subjects With Early Symptomatic AD
This protocol is designed to serve as a pre-screening study for subjects who are potentially eligible for Alzheimer's Disease (AD) therapeutic trials that require tau imaging for inclusion by means of a flortaucipir F18 Positron…
- Trial name
- NCT03467477
- Testing
- Flortaucipir F18, Brain PET Scan
- Where
- 9 sites in United States
- Volunteers
- 161 people
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer's Disease
Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease
The primary objective of the placebo-controlled period is to evaluate the safety and tolerability of BIIB092 in participants with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or with mild AD.
- Trial name
- TANGO (NCT03352557)
- Testing
- BIIB092
- Where
- 101 sites in United States, Australia and 7 more
- Volunteers
- 654 people
- Sponsor
- Biogen
Alzheimer's Disease
Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease
Purpose of the study is to determine whether multiple dose administration of PF-04360365 is safe and well tolerated in patient with mild to moderate Alzheimer's disease.
- Trial name
- NCT00722046
- Testing
- PF-04360365 0.1 mg/kg, PF-04360365 0.5 mg/kg, PF-04360365 1 mg/kg
- Where
- 42 sites in United States, Australia and 4 more
- Volunteers
- 198 people
- Sponsor
- Pfizer